mortality/aging
• mice exhibit significantly increased survival time relative to mice that are homozygous for Ptentm1Hwu and heterozygous for Pgrtm2(cre)Lyd, with >50% of mice still viable at 64 weeks of age
• mice do not die due to the development of endometrial cancer
|
reproductive system
• mice exhibit endometrial hyperplasia at 2 months but not at 3 months of age
• however, endometrial adenocarcinoma with invasion into the myometrium is not observed due to inhibition of ERK1/2 phosphorylation
|
• at 3 months of age, mice show a significantly reduced increase in uterine/body weight ratio relative to mice that are homozygous for Ptentm1Hwu and heterozygous for Pgrtm2(cre)Lyd
|
• at 2 months of age, mice show a significantly reduced uterine epithelial cell proliferation relative to mice that are homozygous for Ptentm1Hwu and heterozygous for Pgrtm2(cre)Lyd
|
neoplasm
• mice develop vaginal papillomas
|